Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21623279 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib
Condition: Lung Cancer
Intervention: Drug: dasatinib

Indicates status has not been verified in more than two years